Menu

ADHD Linked to Structural Differences in the Brain

Imaging data show smaller volumes in several brain regions among people diagnosed with the behavioral disorder.

Feb 21, 2017
Kerry Grens

PIXABAY, TOUBIBE

Update (May 9): The Lancet Psychiatry has published several letters criticizing the study, along with a response from the authors and several corrections.

One letter, written by an independent group of researchers, described a reanalysis of the data controlling for IQ that “found no significant difference between individuals with ADHD and those in the control group.”

Hoogman and colleagues responded that IQ covariation “is the subject of intense discussions in ADHD research, and previous work advises against correcting for IQ. Because a slightly lower IQ can be a feature of ADHD, adjusting for IQ will remove disorder effects in brain regions associated with both ADHD and IQ.”

Update (April 26): A group called Mad in America has gathered more than 800 signatures on a petition to Lancet Psychiatry to retract the paper. “The study is beset by serious methodological shortcomings, missing data issues, and statistical reporting errors and omissions,” the group wrote on its website.

In a statement sent to The Scientist, several of the paper’s authors, including Martine Hoogman, admitted limitations of the study, such as small effect sizes and considerable variation between individuals. “This does not mean that the differences are meaningless,” they added. Hoogman said in an email that an official response will be published in the Lancet Psychiatry in the coming weeks. 

The journal did not immediately respond to a request for comment.

Brain scans of 3,242 volunteers aged four to 63 years old revealed that those diagnosed with attention deficit hyperactivity disorder (ADHD)—roughly half of the group—had smaller tissue volumes in five brain regions. Because the differences were largest between children, the researchers concluded that ADHD likely involves a delay in brain maturation. The study, published in The Lancet Psychiatry on February 15, is the largest of its kind to date, and the authors hope it will change public perception of the disorder.

“I think most scientists in the field already know that the brains of people with ADHD show differences, but I now hope to have shown convincing evidence … that will reach the general public and show that it has [a basis in the brain] just like other psychiatric disorders,” geneticist and coauthor Martine Hoogman of Radboud University in the Netherlands told The Washington Post. “We know that ADHD deals with stigma, but we also know that increasing knowledge will reduce stigma.”

Most pronounced among the brain differences between those with and without ADHD was the amygdala, important for emotional processing. “The amygdala is heavily connected to other brain regions. It is a kind of hub for numerous kinds of signaling around salience and significance of events,” Joel Nigg, a psychiatry professor at Oregon Health & Science University School of Medicine who was not part of the study, told CNN. “The bigger story here is that alterations in amygdala have not been widely accepted as part of ADHD, so seeing that effect emerge here is quite interesting.”

The caudate and putamen were also smaller among participants with ADHD. CNN pointed out that these structures have been associated with the disorder before. "We think it relates to motor control, motivation, cognitive control,” Columbia University’s Jonathan Posner told CNN.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.